EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers

Official title

Phase Ib/II, Open-Label Study of EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers

Overview

This study is to evaluate the safety and antitumor activity of EMB-01 in advanced/metastatic gastrointestinal cancers, including gastric cancer, hepatocellular cancer, cholangiocarcinoma and colorectal cancer.

Detailed description

This is an open-label, Phase Ib/II, multi-stage study of EMB-01 in patients with advanced gastrointestinal tumors including gastric cancer, hepatocellular cancer, cholangiocarcinoma cancer and colorectal cancer, who have EGFR/cMET gene alterations or protein over expression and progressed on available standard therapies and for whom no standard therapy exists that would confer clinical benefit. All patients will be prescreened for cMET and EGFR genetic alterations and protein expression. Only those who met the molecular pre-screening criteria will proceed to clinical screening to determine the eligibility. The study will consist of Phase Ib part and Phase II part, both phases will consist of a molecular prescreening period, screening period, treatment period, safety follow-up period, and disease progression follow-up.

Interventions

• Drug EMB-01
  EMB-01 at the RP2D of 1600 mg will be administered as an IV infusion once weekly (QW) throughout the study. One cycle is defined as 4 weeks (4 doses).

Primary outcome measures

• Number of participants with Adverse Events and Serious Adverse Events as assessed by CTCAE v5.0 [Time frame: Phase 1b, screening up to follow-up (30 days after the last dose)]
• Best Overall Response (BOR) as assessed by RECIST v1.1 [Time frame: Phase II, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months]
• Objective Response Rate (ORR) as assessed by RECIST v1.1 [Time frame: Phase II, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months]
• Duration of Response (DoR) as assess by RECIST v1.1 as assess by RECIST v1.1 [Time frame: Phase II, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months]
• Disease Control Rate (DCR) as assess by RECIST v1.1 [Time frame: Phase II, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months]
• Progression-Free Survival (PFS) as assess by RECIST v1.1 [Time frame: Phase II, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months]
• Maximum serum concentration (Cmax) of EMB-01 [Time frame: Phase Ib only, up to 3 months after first study drug administration]
• Trough serum concentration (Ctrough) of EMB-01 [Time frame: Phase Ib only, predose, through treatment completion, an average of 1 year]
• Area under the concentration-time curve from time 0 (pre-dose) to the time of the dosing interval (AUC0-t) [Time frame: Phase Ib only, up to 3 months after first study drug administration]
• Area under the concentration-time curve from time 0 to infinity (AUC0-inf) [Time frame: Phase Ib only, up to 3 months after first study drug administration]

Secondary outcome measures (10)

• Number of participants with Adverse Events and Serious Adverse Events as assessed by CTCAE v5.0 [Time frame: Phase II, screening up to follow-up (30 days after the last dose)]
• Maximum serum concentration (Cmax) of EMB-01 [Time frame: Phase II, up to 3 months after first study drug administration]
• Trough serum concentration (Ctrough) of EMB-01 [Time frame: Phase II, predose, through treatment completion, an average of 1 year]
• Incidence of positive ADA [Time frame: Phase II , up to the 30-day safety follow-up visit after EOT]
• Best Overall Response (BOR) as assessed by RECIST v1.1 [Time frame: Phase Ib, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months]
• Objective Response Rate (ORR) as assessed by RECIST v1.1 [Time frame: Phase Ib, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months]
• Duration of Response (DoR) as assess by RECIST v1.1 as assess by RECIST v1.1 [Time frame: Phase Ib, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months]
• Disease Control Rate (DCR) as assess by RECIST v1.1 [Time frame: Phase Ib, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months]
• Progression-Free Survival (PFS) as assess by RECIST v1.1 [Time frame: Phase Ib, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months]
• Clinical benefit rate(CBR) as assess by RECIST v1.1 [Time frame: Phase Ib, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months]

Eligibility criteria

Inclusion criteria

Molecular Pre-screening Inclusion criteria

• cMET amplification in tumor sample; OR
• cMET overexpression in tumor sample; OR
• EGFR overexpression in tumor sample; OR
• Other EGFR or cMET gene alteration in blood sample (circulating tumor DNA, ctDNA).

In Phase II, CRC patients must provide blood sample for NGS test, but may not provide tumor samples at prescreening visit. CRC patients don't need to meet the above criteria of EGFR/cMET amplification, overexpression or gene aberration.

Screening Inclusion Criteria

• Able to understand and willing to sign the Informed Consent Form (ICF).
• Histologically/cytologically confirmed advanced/metastatic gastric cancer, HCC, BTC, and colorectal cancer with measurable disease (RECIST V1.1). To be eligible, patients must meet following criteria:

• Have failed all standard of care therapies known to confer clinical benefit. Patients who is not tolerable on standard of care therapies, or no standard of care therapies available, or refused standard of care therapies are eligible.
• Have measurable disease as defined by RESIST v 1.1.
• Archival tumor tissue (formalin-fixed or paraffin-embedded, collected within 1 year) or a new biopsy collected in the molecular pre-screening visit.
• Must have adequate organ function.
• Regarding prior anti-tumor therapy:

• Patients who have received any anticancer drugs approved or investigational, including chemotherapy, immune therapy, hormonal therapy (Exceptions: hormone-replacement therapy, testosterone or oral contraceptives), biologic therapy, must have stopped treatment at least 4 weeks or within 5 half -lives whichever shorter before first dose of EMB-01.
• Local radiotherapy or radiation therapy for bone metastases must have stopped 2 weeks before first dose of EMB-01. No therapeutic radiopharmaceuticals are taken within 8 weeks before first dose of EMB-01.
• Patients who have received prior targeted therapies must have stopped treatment for at least 4 weeks or within 5 half-lives, whichever is shorter before first dose of EMB-01.
• Female patient with fertility or male patient whose partner has fertility should use one or more contraceptive methods for contraception starting from screening period and continue throughout the study treatment and for 3 months.
• ECOG score ≤1.

Exclusion criteria

Molecular Pre-screening Exclusion Criteria

Subject who meets any of the following criteria can't be proceeded to clinical screening:

• Patients who are unwilling to sign the molecular pre-screening ICF.
• Patients for whom the results of central laboratory testing do not meet the molecular pre-screening inclusion criteria.
• Patients with a documented gene alteration including but not limited to HER2, KRAS, NRAS, BRAF, NTRK, ALK, RET, ROS1, and FGFR, etc. that is known to confer resistance to EGFR and/or cMET inhibitors.\* \* In Phase II, CRC patients with activated KRAS, NRAS or BRAF mutation should be excluded, but patients with other gene alterations do not need to be excluded.

Screening Exclusion Criteria

• Life expectancy < 3 months.
• Patients with primary central nervous system (CNS) malignancy or symptomatic CNS (leptomeningeal or brain) metastases are not allowed. Patients with asymptomatic CNS metastases are eligible.
• Pregnant or nursing females.
• Patients who have had major surgery within the 28 days from the screening. Surgical wounds must be completely healed.
• Any other serious underlying medical (e.g. uncontrolled diabetes mellitus, active uncontrolled infection, active gastric ulcer, uncontrolled seizures, cerebrovascular incidents, gastrointestinal bleeding, severe signs and symptoms of coagulation and clotting disorders, cardiac conditions), psychiatric, psychological, familial or geographical condition that, in the judgment of the investigator, may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

China · 13 centers

• Beijing cancer Hospital — Beijing
• Nanfang Hospital — Guangzhou
• Hunan Cancer Hospital — Changsha
• West China Hospital, Sichuan University — Chengdu
• The Sixth Affiliated Hospital of Sun Yat-Sen University — Guangzhou
• Sir Run Run Shaw Hospital, Zhejiang University School of Medicine — Hangzhou
• Harbin Medical University Cancer Hospital — Harbin
• Shandong Cancer Hospital — Jinan
• … and 5 more centers

United States · 1 center

• MD Anderson Cancer Center — Houston

Identifiers

NCT: NCT05176665 · EMB01X201

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗